Tolebrutinib reduces disability progression in nonrelapsing secondary progressive multiple sclerosis
1. In this randomized controlled trial of patients with nonrelapsing secondary progressive multiple sclerosis (SPMS), oral tolebrutinib reduced the risk ...
